James P. Allison received the 2014 Szent-Györgi Prize for Progress in Cancer Research.

Q Medicine 癌症 Pub Date : 2014-09-01 DOI:10.5732/cjc.014.10125
Jie Zhao, Peter Scully, Sujuan Ba
{"title":"James P. Allison received the 2014 Szent-Györgi Prize for Progress in Cancer Research.","authors":"Jie Zhao,&nbsp;Peter Scully,&nbsp;Sujuan Ba","doi":"10.5732/cjc.014.10125","DOIUrl":null,"url":null,"abstract":"<p><p>The Szent-Györgyi Prize for Progress in Cancer Research is a prestigious scientific award established by the National Foundation for Cancer Research (NFCR) -- a leading cancer research charitable organization in the United States that is committed to supporting innovative cancer research on the global scale that aims to cure cancer. Each year, the Szent-Györgyi Prize honors an outstanding researcher whose original discoveries have expanded our understanding of cancer and resulted in notable advances in cancer prevention, diagnosis, or treatment. The prize also promotes public awareness of the importance of basic cancer research and encourages the sustained investment needed to accelerate the translation of these research discoveries into new cancer treatments. This report highlights the history and mission of the Szent-Györgyi Prize, its role in promoting discovery-oriented cancer research, and the pioneering work led by the 2014 prize winner, Dr. James Allison. Dr. Allison's work in the area of cancer immunotherapy led to the successful development of immune checkpoint therapy, and the first drug approved by the United States Food and Drug Administration for the treatment of metastatic melanoma. </p>","PeriodicalId":10034,"journal":{"name":"癌症","volume":"33 9","pages":"416-20"},"PeriodicalIF":0.0000,"publicationDate":"2014-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cc/49/cjc-33-09-416.PMC4190431.pdf","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"癌症","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5732/cjc.014.10125","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 3

Abstract

The Szent-Györgyi Prize for Progress in Cancer Research is a prestigious scientific award established by the National Foundation for Cancer Research (NFCR) -- a leading cancer research charitable organization in the United States that is committed to supporting innovative cancer research on the global scale that aims to cure cancer. Each year, the Szent-Györgyi Prize honors an outstanding researcher whose original discoveries have expanded our understanding of cancer and resulted in notable advances in cancer prevention, diagnosis, or treatment. The prize also promotes public awareness of the importance of basic cancer research and encourages the sustained investment needed to accelerate the translation of these research discoveries into new cancer treatments. This report highlights the history and mission of the Szent-Györgyi Prize, its role in promoting discovery-oriented cancer research, and the pioneering work led by the 2014 prize winner, Dr. James Allison. Dr. Allison's work in the area of cancer immunotherapy led to the successful development of immune checkpoint therapy, and the first drug approved by the United States Food and Drug Administration for the treatment of metastatic melanoma.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
James P. Allison获得了2014年Szent-Györgi癌症研究进展奖。
Szent-Györgyi癌症研究进步奖是由美国国家癌症研究基金会(NFCR)设立的一项享有声望的科学奖项。NFCR是美国领先的癌症研究慈善组织,致力于在全球范围内支持旨在治愈癌症的创新癌症研究。每年,Szent-Györgyi奖都会表彰一位杰出的研究人员,他们的原创发现扩大了我们对癌症的了解,并在癌症预防、诊断或治疗方面取得了显著进展。该奖项还促进公众对基础癌症研究重要性的认识,并鼓励持续投资,以加速将这些研究发现转化为新的癌症治疗方法。本报告重点介绍了Szent-Györgyi奖的历史和使命,它在促进以发现为导向的癌症研究方面的作用,以及2014年获奖者詹姆斯·艾利森博士领导的开创性工作。Allison博士在癌症免疫治疗领域的工作导致了免疫检查点疗法的成功开发,以及美国食品和药物管理局批准的第一种用于治疗转移性黑色素瘤的药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
癌症
癌症 ONCOLOGY-
CiteScore
3.47
自引率
0.00%
发文量
9010
审稿时长
12 weeks
期刊介绍: In July 2008, Landes Bioscience and Sun Yat-sen University Cancer Center began co-publishing the international, English-language version of AI ZHENG or the Chinese Journal of Cancer (CJC). CJC publishes original research, reviews, extra views, perspectives, supplements, and spotlights in all areas of cancer research. The primary criteria for publication in CJC are originality, outstanding scientific merit, and general interest. The Editorial Board is composed of members from around the world, who will strive to maintain the highest standards for excellence in order to generate a valuable resource for an international readership.
期刊最新文献
New strategies for CAR-T cell in the treatment of solid tumors Effect of myeloid-derived suppressor cells on B cell function in mice bearing breast cancer The relationship of microsatellite instability with infiltration of T lymphocytes in tissues of non-small cell lung cancer Influence of VEGF-C/VEGFR3 signaling pathway on dendritic cells derived from peripheral blood of tumor patients MCP-1/CCR2 axis promotes the homing of human umbilical cord mesenchymal stem cells to lung cancer tissues
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1